<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773967</url>
  </required_header>
  <id_info>
    <org_study_id>1 R01 HD071915-02</org_study_id>
    <nct_id>NCT01773967</nct_id>
  </id_info>
  <brief_title>Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis</brief_title>
  <official_title>Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will study the efficacy and side effect profile of LGG, a probiotic, in
      pediatric patients with acute gastroenteritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter randomized controlled trial of LGG in patients 3-48 months of age presenting to
      the Emergency Department with acute gastroenteritis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Modified Vesikari Score</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>presence of severe adverse events up to 1 year after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>LGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGG 10^10 cfu PO bid x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>micro-crystalline cellulose PO bid x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGG</intervention_name>
    <description>LGG 10^10 cfu PO BID X 5 days</description>
    <arm_group_label>LGG</arm_group_label>
    <other_name>Lactobacillus GG ATCC 53103</other_name>
    <other_name>Lactobacillus rhamnosus</other_name>
    <other_name>culturelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micro-crystalline cellulose</intervention_name>
    <description>1 capsule PO bid x 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo micro-crystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 3-48 months (have not yet reached their fourth birthday); AND

          2. Presence of 3 or more watery stools within 24 hours of screening; AND

          3. Duration of vomiting or diarrhea less than 7 days; AND

          4. Symptoms consistent with acute intestinal infectious process.

        Exclusion Criteria:

          1. Presence of an indwelling vascular access line; OR

          2. Presence of structural heart disease excluding non-pathological heart murmurs; OR

          3. Receiving immunosuppressive therapy or history of immunodeficiency; OR

          4. Hematochezia in the preceding 48 hours; OR

          5. Chronic gastrointestinal problems (e.g. short gut syndrome, inflammatory bowel
             disease); OR

          6. Patients with known pancreatitis; OR

          7. Critically ill patients; OR

          8. Family member with an indwelling vascular access line, or on immunosuppressive
             therapy, or with a known immunodeficiency; OR

          9. Bilious emesis; OR

         10. Probiotic use (supplement) in the preceding 2 weeks; OR

         11. Allergy to lactobacillus or Microcrystalline Cellulose (MCC); OR

         12. Allergy to erythromycin, clindamycin, AND Beta-lactam antibiotics (all); OR

         13. Patients who have already been enrolled in the study once; OR

         14. Not available for daily follow-up while symptomatic; OR

         15. Parent/guardian not speaking English or Spanish.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Schnadower, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Schnadower, MD</last_name>
    <phone>314 747 5604</phone>
    <email>schnadower_d@kids.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phillip I Tarr, MD</last_name>
    <phone>314 286 2848</phone>
    <email>Tarr@kids.wustl.edu</email>
  </overall_contact_backup>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>David Schnadower</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus rhamnosus GG</keyword>
  <keyword>LGG</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>acute gastroenteritis</keyword>
  <keyword>child</keyword>
  <keyword>pediatric</keyword>
  <keyword>RCT</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
